IL17A and histiocytic sarcoma: The clinical outcomes mostly deriving from a trial setting strengthen the role of IL-17 in the pathogenesis of HS and highlight the potential of targeting this cytokine to offer patients a novel, effective, and well-tolerated treatment option in the management of this challenging disease.